Detailed Information
Cited 2 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
Phase IIb/III double-blind randomized trial of BIBW 2992, an irreversible, dual inhibitor of EGFR and HER2 plus best supportive care (BSC) versus placebo plus BSC in patients with NSCLC failing 1-2 lines of chemotherapy (CT) and erlotinib or gefitinib (LUX-Lung1): A preliminary report
- Authors
- Yang, C[Yang, C.]; Hirsh, V[Hirsh, V.]; Cadranel, J[Cadranel, J.]; Chen, Y[Chen, Y.]; Park, K[Park, K.]; Kim, S[Kim, S.]; Chao, T[Chao, T.]; Oberdick, M[Oberdick, M.]; Shahidi, M[Shahidi, M.]; Miller, V[Miller, V.]
- Issue Date
- 20-May-2009
- Publisher
- AMER SOC CLINICAL ONCOLOGY
- Citation
- JOURNAL OF CLINICAL ONCOLOGY, v.27, no.15
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF CLINICAL ONCOLOGY
- Volume
- 27
- Number
- 15
- ISSN
- 0732-183X
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.